Vanda Pharmaceuticals | VNDA - Spese Di Vendita E Di Amministrazione

Prezzo Delle Azioni
7.26
Cambio Giornaliero
0.44 6.45%
Mensile
-15.58%
Annuale
52.20%
Q1 Previsione
6.91




Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
J&J USD 6.75B 831M 2025-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 308M 40M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Veracyte USD 43.31M 8.43M 2025-12